SAS Output

10-APR-2021 6:10

MMYEL ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1304-MM,relapsed/refractory, Car+Dex 1 N 1 Dex+Low Dose Carfilzomib 140 72 0 0 0 0 0 02/12/2014    
        2 Dex+High Dose Carfilzomib   71 0 0 0 0 0      
            143 0 0 0 0 0      
 
    2 Y 3 Dex+High Dose Carfilzomib 140 22 0 0 0 0 0 02/12/2014    
            22 0 0 0 0 0      
 
  S1803-MM, Maintenance, Len vs Len/Dara 1 Y 0 Screening 1100 445 330 210 103 24 4 08/13/2019 260 99
            445 330 210 103 24 4      
 
    2 Y 1 Lenalidomide 1100 196 156 104 52 13 3 08/13/2019    
        2 Lenalidomide + Daratumumab   192 152 104 51 15 2      
            388 308 208 103 28 5      
 
No A061402-Solitary Plasmacytoma, adj sys+Zol vs Zol 0 E Total Registrations   1 0 0 0 0 0 01/27/2017    
            1 0 0 0 0 0      
 
  EAA173-MYEL, SMM, Rd +/- Daratumumab 0 E Total Registrations   26 19 8 4 4 1 01/08/2020 208 82
            26 19 8 4 4 1      
 
    1 E Total Registrations   13 8 4 1 1 1 01/08/2020    
            13 8 4 1 1 1      
 

10-APR-2021 6:10

MMYEL Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date # of
ACT.
INSTs
# of
CURR
IRBs
S1803 MM, Maintenance, Len vs Len/Dara 3 Second Randomization 27-Jun-19 260 99